Welcome to our dedicated page for INTELGENX TECHS news (Ticker: IGXT), a resource for investors and traders seeking the latest updates and insights on INTELGENX TECHS stock.
IntelGenx Technologies Corp., based in Montreal, is dedicated to developing innovative proprietary technologies for enhanced drug delivery. The company's business strategy involves leveraging these technologies to enhance existing drug compounds with proven efficacy and safety. Through collaborations with strategic partners, IntelGenx reintroduces these compounds to the market as branded products with improved deliverability and efficacy. The company offers full-service pharmaceutical development, including formulation, clinical development, regulatory activities, manufacturing, and packaging. IntelGenx's experienced team works with both new chemical entities and established therapeutic active pharmaceutical ingredients, utilizing innovative drug delivery systems for a competitive edge and product extension opportunities.
IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) has officially responded to the Complete Response Letter (CRL) from the FDA regarding its New Drug Application for RIZAPORT® VersaFilm®, originally received in March 2020. The company is optimistic following discussions with the FDA, believing that their submission addresses all required additional Chemistry, Manufacturing, and Controls information. IntelGenx aims to provide this medication for acute migraine patients in collaboration with the FDA.
IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) has announced a collaboration update with atai Life Sciences for developing pharmaceutical-grade psychedelic formulations using IntelGenx's polymeric film technologies. The buccal film candidate, VLS-01, contains a synthetic form of N,N-dimethyltryptamine and is aimed at treating treatment-resistant depression (TRD). The initial dosing in the Phase 1 clinical trial has commenced, with topline results expected in H1 2023. This move marks a significant milestone for IntelGenx as they explore innovative drug delivery methods.
IntelGenx announced that patient enrollment in the Montelukast VersaFilm® Phase 2a clinical trial for Alzheimer's Disease has reached the halfway mark, with a goal of 70 patients across up to eight sites. CEO Dr. Horst Zerbe expressed optimism regarding the enrollment pace, anticipating completion by year-end 2022. The Montelukast formulation aims to enhance bioavailability and compliance for patients. Prior Phase 1 studies indicated significant safety and effectiveness advantages over traditional tablet forms, suggesting a promising avenue for addressing neurodegenerative conditions.
IntelGenx Technologies Corp. (TSX:IGX) announced its financial results for Q2 2022, reporting revenue of $398,000, up from $162,000 in Q2 2021, marking a 146% increase. However, the net comprehensive loss widened to $3.2 million, compared to $2.5 million in the previous year. Adjusted EBITDA loss was $2.0 million, up from $1.7 million in Q2 2021. Operating costs grew to $2.6 million, reflecting increased operational expenses. Cash and short-term investments stood at $7.0 million as of June 30, 2022.
IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) announced it will release its second quarter 2022 financial results after market close on August 11, 2022. The conference call, featuring CEO Dr. Horst G. Zerbe and CFO Andre Godin, will provide insights into the results and a business update. Interested parties can participate via phone or through a live webcast on the company's website. IntelGenx specializes in pharmaceutical films and offers innovative drug delivery solutions to address unmet medical needs.
IntelGenx Technologies Corp. announced the issuance of 19,381,223 shares at a deemed price of C$0.2812 for the payment of C$5,450,000 in convertible debentures due June 30, 2022. Additionally, 573,684 shares were issued, valued at C$0.38 each, for C$218,000 in interest payments. The convertible debentures have been delisted from the Toronto Stock Exchange under the symbol IGX.DB as of the same date. IntelGenx is known for its innovative drug delivery systems and comprehensive pharmaceutical services.
IntelGenx Technologies Corp. (TSX:IGX) plans to issue shares to settle outstanding convertible unsecured subordinated debentures totaling C$5,450,000 due June 30, 2022. Additionally, it will issue 573,684 Shares at C$0.38 each for C$218,000 interest owed. This move complies with the trust indenture terms, allowing repayment in Shares at 95% of the market price. The issuance is subject to Toronto Stock Exchange acceptance and will leverage exemptions from applicable securities laws.
IntelGenx Technologies (TSX:IGX) (OTCQB:IGXT) reported a net loss of $3.0 million for Q1 2022, higher than the $2.3 million loss in Q1 2021. Revenue decreased by 17% to $237,000, primarily due to a drop in product revenues. Adjusted EBITDA loss widened to $2.1 million from $1.7 million year-over-year. However, cash and short-term investments rose significantly to $10.2 million compared to $2.0 million in March 2021. The company resumed patient dosing in its Phase 2a 'BUENA' clinical trial targeting Alzheimer’s Disease, a positive step for its product pipeline.
IntelGenx Technologies Corp. held its Annual Meeting of Shareholders on May 10, 2022, where shareholders approved all proposed items, including the election of eight directors and the ratification of Richter LLP as independent auditors for 2022. A total of 105,395,585 shares (68.15%) were present or represented by proxy. Voting results showed strong support for nominees, with Horst G. Zerbe receiving 90.72% approval. IntelGenx specializes in pharmaceutical film technologies, focusing on innovative product development to address unmet medical needs.
IntelGenx Technologies Corp. (TSX:IGX) has announced the release date for its first quarter 2022 financial results, scheduled for May 12, 2022, after market close. A conference call led by CEO Dr. Horst G. Zerbe and CFO Andre Godin will follow at 4:30 p.m. ET to discuss the results and provide a business update. The event will be accessible via phone and live webcast on the company's website.
IntelGenx specializes in pharmaceutical films and is recognized for its innovative technologies aimed at addressing unmet medical needs.
FAQ
What is the current stock price of INTELGENX TECHS (IGXT)?
What is the market cap of INTELGENX TECHS (IGXT)?
What is the primary focus of IntelGenx Technologies Corp.?
How does IntelGenx enhance existing drug compounds?
What is IntelGenx's business strategy?
What services does IntelGenx offer?
What types of active pharmaceutical ingredients does IntelGenx work with?
What advantage do innovative drug delivery systems offer IntelGenx?
Who can be contacted for investor relations at IntelGenx?
Who is the President and CFO of IntelGenx Corp.?
Where can copies of the SISP Order and procedures be obtained?
How can U.S. persons direct inquiries regarding IntelGenx?
